Streetbeat News

LENZ

LENZ Therapeutics, Inc.

Industry

Biotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Open

25.17

Mkt cap

700M

Volume

297K

High

25.65

P/E Ratio

-9.29

52-wk high

38.93

Low

24.78

Div yield

0.28

52-wk low

2.57

LENZ Therapeutics will report its Q4 and full year 2024 financial results on March 19, 2025. The company focuses on developing aceclidine-based eye drops for presbyopia.

Portfolio Pulse from

March 11, 2025 | 12:15 pm

LENZ Therapeutics, a biopharmaceutical company, will host a Commercial Day on April 15, 2025, to discuss its commercialization strategy for LNZ100, an aceclidine-based eye drop for presbyopia. The event aims to highlight progress towards potential approval.

Portfolio Pulse from

March 03, 2025 | 1:15 pm

LENZ Therapeutics, a pre-commercial biopharmaceutical company, will participate in upcoming investor conferences. The company focuses on developing aceclidine-based eye drops for presbyopia.

Portfolio Pulse from

February 24, 2025 | 1:15 pm

LENZ Therapeutics, Inc. (LENZ) has formed a hammer chart pattern, suggesting it has found support. Coupled with upward earnings estimate revisions, this indicates a potential trend reversal and makes it a 'buy the bottom' stock.

Portfolio Pulse from

November 18, 2024 | 4:00 pm

LENZ Therapeutics, a pre-commercial biopharmaceutical company, will participate in upcoming investor conferences. The company focuses on developing aceclidine-based eye drops for presbyopia.

Portfolio Pulse from

November 12, 2024 | 1:15 pm

LENZ Therapeutics, Inc. (LENZ) has seen a 3.37% increase in its stock price over the past week, raising questions about its potential as a top pick for momentum investors.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

LENZ Therapeutics, Inc. held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 06, 2024 | 5:00 pm

LENZ Therapeutics' investigational drug LNZ100 for presbyopia has shown positive results in a Phase 3 trial in China, potentially strengthening its position for partnerships outside the U.S. The drug met primary and secondary endpoints, showing significant improvement in visual acuity. The FDA has accepted LENZ's marketing application for LNZ100, with a PDUFA date set for August 8, 2025.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 5:51 pm

LENZ Therapeutics shares rise following positive Phase 3 trial results for LNZ100 in China, in collaboration with CORXEL.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 10:54 am

LENZ Therapeutics shares rose 18% in pre-market trading following positive Phase 3 trial results in China. Other notable pre-market movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI, with significant gains, while SMX and Upexi saw declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 10:32 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.